“Cannabidiol (CBD) is a nonpsychoactive phytocannabinoid with anti-inflammatory activity mediated by enhancing adenosine signaling.
As the adenosine A1 receptor activation confers protection against ischemia/reperfusion (I/R)-induced ventricular arrhythmias, we hypothesized that CBD may have antiarrhythmic effect through the activation of adenosine A1 receptor.
Cannabidiol has recently been shown to suppress ischemia-induced ventricular arrhythmias…
The present results demonstrated that CBD has an antiarrhythmic effect against I/R-induced arrhythmias, and the antiarrhythmic effect of CBD may be mediated through the activation of adenosine A1 receptor.”
“Activation of cannabinoid CB(2) receptors protects against various forms of ischaemia-reperfusion (I/R) injury.
Δ(8) -Tetrahydrocannabivarin (Δ(8) -THCV) is a synthetic analogue of the plant cannabinoid Δ(9) -tetrahydrocannabivarin, which exhibits anti-inflammatory effects in rodents involving activation of CB(2) receptors. Here, we assessed effects of Δ(8) -THCV and its metabolite 11-OH-Δ(8) -THCV on CB(2) receptors and against hepatic I/R injury.
CONCLUSIONS AND IMPLICATIONS:
Δ(8) -THCV activated CB(2) receptors in vitro, and decreased tissue injury and inflammation in vivo, associated with I/R partly via CB(2) receptor activation.”
“The phytocannabinoid, Delta(9)-tetrahydrocannabivarin (THCV), can block cannabinoid CB(1) receptors… THCV can activate CB(2) receptors… THCV can activate CB2 receptors and decrease signs of inflammation and inflammatory pain in mice partly via CB1 and/or CB2 receptor activation…
Because there is evidence that THCV can behave as a CB1 receptor antagonist in vivo, it would also be of interest to explore the possibility that this compound can suppress unwanted symptoms in animal models of disorders in which symptoms can be ameliorated by a combination of CB2 receptor activation and CB1 receptor blockade…” http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2931567/
“Shona Banda was diagnosed with Crohn’s disease… She underwent several surgeries and was put on several pharmaceuticals, but her condition worsened progressively until she was considered terminal. She was bedridden… wasting away… She was waiting to die.
She managed to see Rick Simpson’s Run from the Cure…”
“Although she had been smoking marijuana to ease pain and help her sleep and eat, she had no way of making the oil, which required a pound of marijuana to produce the two ounces of cannabis oil she would need to heal.
Shona was in a funk about the lack of enough hemp to make her own oil when her husband noticed specks of oil residue in the inside of the vaporizer’s glass globe cover.
So she took the inhalation tube out of the vaporizer and sealed it, then simply collected those little blobs of oil from the inside of the glass globe with a spatula.
She did this three times a day, putting the collected oil residue into a capsule and taking it. After a very few days, Shona could walk without a cane. Soon she began eating and sleeping better and putting on weight. It wasn’t long before she was completely weened off all her pharmaceuticals.
She started a journal as she began getting better. The journal has become a book called Live Free or Die. The title is a reference to health freedom. Now she is very healthy and active.”
“Crohn’s Disease Survivor Shona Banda Tells How Medical Marijuana Oil Helps Her “Live Free”” https://www.youtube.com/watch?v=x_otUB7pVMA
“Ben Swann Radio: Shona Banda Explains Her Remarkable Story On How Cannabis Oil Saved Her Life. After being diagnosed with Crohn’s disease in 2002, Shona Banda went through the struggles that many suffer with when battling the autoimmune disease. On the Ben Swann Radio Show, Ben and Shona discussed her tribulations while suffering from the disease and her immediate experiences after finding the cure to her disease.”
“Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the major nonpsychotropic compound of Cannabis sativa.
Basic research studies have provided strong evidence for safety and anticonvulsant properties of CBD. However, the lack of pure, pharmacologically active compounds and legal restrictions have prevented clinical research and confined data on efficacy and safety to anecdotal reports.
Pure CBD appears to be an ideal candidate among phytocannabinoids as a therapy for treatment-resistant epilepsy.
A first step in this direction is to systematically investigate the safety, pharmacokinetics, and interactions of CBD with other antiepileptic drugs and obtain an initial signal regarding efficacy at different dosages. These data can then be used to plan double-blinded placebo-controlled efficacy trials.”
“Cannabis has been used to treat disease since ancient times. Δ9 -Tetrahydrocannabinol (Δ9 -THC) is the major psychoactive ingredient and CBD is the major nonpsychoactive ingredient in cannabis.
Cannabis and Δ9 -THC are anticonvulsant in most animal models but can be proconvulsant in some healthy animals. The psychotropic effects of Δ9 -THC limit tolerability.
CBD is anticonvulsant in many acute animal models, but there are limited data in chronic models.
The antiepileptic mechanisms of CBD are not known, but may include effects on the equilibrative nucleoside transporter; the orphan G-protein-coupled receptor GPR55; the transient receptor potential of vanilloid type-1 channel; the 5-HT1a receptor; and the α3 and α1 glycine receptors.
CBD has neuroprotective and antiinflammatory effects, and it appears to be well tolerated in humans, but small and methodologically limited studies of CBD in human epilepsy have been inconclusive.
More recent anecdotal reports of high-ratio CBD:Δ9 -THC medical marijuana have claimed efficacy, but studies were not controlled.
CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic-ischemic encephalopathy.”
“Charlotte, a little girl with SCN1A-confirmed Dravet syndrome, was recently featured in a special that aired on CNN. Through exhaustive personal research and assistance from a Colorado-based medical marijuana group (Realm of Caring), Charlotte’s mother started adjunctive therapy with a high concentration cannabidiol/Δ9 -tetrahydrocannabinol (CBD:THC) strain of cannabis, now known as Charlotte’s Web. This extract, slowly titrated over weeks and given in conjunction with her existing antiepileptic drug regimen, reduced Charlotte’s seizure frequency from nearly 50 convulsive seizures per day to now 2-3 nocturnal convulsions per month. This effect has persisted for the last 20 months, and Charlotte has been successfully weaned from her other antiepileptic drugs. We briefly review some of the history, preclinical and clinical data, and controversies surrounding the use of medical marijuana for the treatment of epilepsy, and make a case that the desire to isolate and treat with pharmaceutical grade compounds from cannabis (specifically CBD) may be inferior to therapy with whole plant extracts. Much more needs to be learned about the mechanisms of antiepileptic activity of the phytocannabinoids and other constituents of Cannabis sativa.”
“Scientists are looking at the potential use of cannabis to treat and potentially cure severe forms of epilepsy.
The medical benefits of medical marijuana for neurological conditions like epilepsy are highly debated.
Examining the potential use of the drug, a series of articles in the journal Epilepsia, a journal of the International League Against Epilepsy, looks at its potential use for treating the syndrome.
Edward Maa, from the Comprehensive Epilepsy Program at Denver Health in Denver, Colorado, looks at a case study of a child with Dravet syndrome – a very severe form of epilepsy.
In the case, a mother provided her child with a strain of medical marijuana high in Cannabidiol (CBD) and tetrahydrocannabinol (THC) known as Charlotte’s Web.
When used with the child’s normal drug regime, seizures dropped from 50 convulsions per day to just two or three per month.”
“Two-year-old Kyla Williams hasn’t learned to walk or talk, her development has stopped as she suffered as many as 200 seizures daily and no medication helped. Now the girl’s family says she hasn’t had a seizure in a week, ever since they began giving her cannabis oil extracted from hemp.
The oil being used by the toddler has high amounts of cannabidiol, known as CBD, the main ingredient in medical marijuana, and almost no psychoactive ingredients.”